tiprankstipranks
Advertisement
Advertisement

Echo IQ Accelerates U.S. Rollout as EchoSolv Usage Surges and Mayo, Mount Sinai Deals Advance

Story Highlights
  • Echo IQ is rapidly scaling its EchoSolv cardiology AI platform in the U.S., adding Mayo and Mount Sinai while sharply lifting clinical usage.
  • Expanded U.S. sales coverage, strong pipeline, advancing FDA pathway and IP protection position Echo IQ for broader commercial rollout.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Echo IQ Accelerates U.S. Rollout as EchoSolv Usage Surges and Mayo, Mount Sinai Deals Advance

Claim 55% Off TipRanks

EchoIQ Limited ( (AU:EIQ) ) has shared an update.

Echo IQ reported strong U.S. commercial momentum in the March quarter, highlighted by a distribution agreement with Mayo Clinic for EchoSolv HF once cleared, deployment of EchoSolv AS at New York’s Mount Sinai Health System, and a pipeline of more than 50 active U.S. accounts. Usage of EchoSolv AS climbed about 131% quarter-on-quarter to 9,220 echocardiograms, with flagship customer Beth Israel in Boston operating at full capacity, reinforcing the platform’s scalability in high-throughput clinical settings.

The company expanded its U.S. sales and implementation team to secure four-region coverage and is actively targeting over 250 high-volume echocardiography centres, supporting a scalable land-and-expand strategy across major hospital networks. Echo IQ also advanced its broader platform roadmap and defensibility, progressing EchoSolv HF through the FDA 510(k) pathway, building clinical and health economics evidence, filing new patents and trademarks, and maintaining a cash balance of $11.14 million to support near-term U.S. commercialization and potential strategic partnerships.

The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.

More about EchoIQ Limited

Echo IQ Limited is an Australian AI-driven medical technology company focused on cardiology, developing software that analyses echocardiograms to detect and manage structural heart disease and related conditions. Its flagship EchoSolv platform targets high-volume hospital and health system echocardiography labs in the U.S., with modules for aortic stenosis and, pending clearance, heart failure, and additional cardiac indications in development.

Average Trading Volume: 2,924,675

Technical Sentiment Signal: Buy

Current Market Cap: A$756.7M

For detailed information about EIQ stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1